Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers (Q34531106)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

title

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

main subject

placebo

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Veit J Erpenbeck

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Eva Vets

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Lien Gheyle

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Wande Osuntokun

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Michael Larbig

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Srikanth Neelakantham

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

David Sandham

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Gerald Dubois

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Walid Elbast

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Paul Goldsmith

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

Markus Weiss

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

publication date

28 March 2016

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

published in

Clinical pharmacology in drug development

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

volume

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

page(s)

306-313

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

cites work

Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Novel CRTH2 antagonists: a review of patents from 2006 to 2009.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Emerging roles of DP and CRTH2 in allergic inflammation

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Release of prostaglandin D2 into human airways during acute antigen challenge

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

7 July 2018

Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of "chemoattractant receptor homologous molecule expressed on Th2 cells" (CRTH2).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCPDD.244

retrieved

21 January 2018

Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5071756

retrieved

27 October 2018

Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCPDD.244

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCPDD.244

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCPDD.244

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/CPDD.244

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

PMC publication ID

5071756

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

PubMed publication ID

27310331

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27310331

retrieved

2 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34531106&oldid=2143868410"